A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaı̈ve patients with metastatic or locally advanced non-small cell lung cancer

Abstract

Docetaxel-cisplatin is an effective and well-tolerated treatment in Asian patients with NSCLC.

A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan

“…Efficacy appears to be similar for the two schedules, regardless of the disease, while weekly docetaxel is significantly less myelotoxic. Phase II weekly docetaxel plus cisplatin treatment also showed less myelotoxicity [16][17][18][19]. Currently, tri-weekly docetaxel remains the standard schedule for treatment, whereas the weekly schedule offers an option for patients with whom the risk of myelosuppression is considered unacceptable [20].…”

Docetaxel and Cisplatin Regimen for Non-Small-Cell Lung Cancer

“…[17][18][19][20] The studies reviewed reported mild (grade 1 or 2) nausea or vomiting in 15% to 65% of patients 5,12 and severe (grade 3 or 4) nausea or vomiting in 5% to 13% of patients. [2][3][4][5]12 The antiemetic therapy should continue for at least 3 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (more than 24 hours) use of these agents, making a steroid, or steroid and dopamine antagonist combination, most appropriate for follow-up therapy.…”

“…F. Pulmonary: Docetaxel can cause fluid retention, including pleural effusion, ascites, and peripheral edema, in up to 27% of patients. 30 In the DC trials reviewed, mild (grade 1 or 2) edema was reported in 95% of patients, 12 and severe (grade 3) edema was reported in 1% of patients. 12 Patients should be treated with a steroid (eg, dexamethasone 8 mg to 10 mg PO twice daily) for 3 to 5 days, beginning the day before docetaxel administration.…”

Docetaxel and Cisplatin (DP) Regimen for Solid Tumors

“…58 The studies reviewed reported severe (grade 3 or 4) nausea or vomiting in 1.4% to 30% of patients. 2,12,17,19,25,38,39,41,43,44,47-49,53,54 Sengelov et al reported mild nausea or vomiting in 32%, and severe nausea or vomiting in 14% of patients, respectively. 53 According to current guidelines, appropriate acute emesis prophylaxis includes a serotonin antagonist, a corticosteroid and a neurokinin inhibitor.…”

“…Using a number of different doses and treatment schedules, docetaxel and cisplatin have been reported as useful for primary and salvage therapy of breast 1-5 , esophageal 6 , gastric 7-13 , head and neck 14-22 , nasopharyngeal 23–24 , non-small-cell lung 25-47 , ovarian 48–49 and urothelial 50-53 cancers, and cancers of unknown primary 54 . Current guidelines recommend the combination as first-line therapy for advanced non-small cell lung cancer.…”